SXTPNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTPW
60 DEGREES PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.83−0.03 (-3.29%)
Close on Oct 19, 2026
- Market cap
- $2.20M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0M
Shares held, 13F filers
Institutional holders
8
3 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $30.09K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Knight Therapeutics Inc. | 658,629 | 19.85% | 13G (passive) | Jul 22, 2026 |
| Armistice Capital, LLC | 476,866 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Daniel B. Asher | 372,429 | 9.99% | 13G (passive) | Jul 15, 2025 |
| Orca Capital AG | 320,000 | 9.90% | 13G (passive) | Jul 15, 2025 |
| Intracoastal Capital LLC | 263,158 | 9.10% | 13G (passive) amendment | Mar 31, 2026 |
| Heights Capital Management, Inc. | 197,911 | 7.00% | 13G (passive) amendment | Mar 31, 2026 |
| Lind Global Partners III LLC | 191,571 | 5.45% | 13G (passive) | Jul 31, 2026 |
| Ayrton Capital LLC | 163,480 | 9.99% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SXTP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Kathmere Capital Management, LLC | 265,100 | – | $466.58K | +120,417 | 0.02% |
| Citadel Advisors LLC | 22,362 | – | $39.36K | New | 0.00% |
| XTX Topco Ltd | 17,639 | – | $31.05K | New | 0.00% |
| Kovack Advisors, Inc. | 15,000 | – | $26.40K | New | 0.00% |
| Geode Capital Management, LLC | 14,551 | – | $25.61K | −1,744 | 0.00% |
| UBS Group AG | 13,592 | – | $23.92K | −17,818 | 0.00% |
| Barclays PLC | 1,052 | – | $1.85K | −804 | 0.00% |
| Osaic Holdings, Inc. | 25 | – | $44 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 3 / 1 | 3 / 3 | 0M | 0M |
| Q1 2026 | 8 | 0M | 8 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SXTP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 11,788 | – | $17.56K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -300 | – | -$528 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Geoffrey S. Dow | President and CEO, Director | 35,250 | Jun 15, 2026 |
| Kristen Landon | Chief Operating Officer | 4,540 | Aug 14, 2025 |
| Tyrone Miller | CFO | 26,370 | Jan 24, 2025 |
| Eric Francois | Director | – | May 19, 2026 |
| Cheryl Xu | Director | 13,816 | Jun 5, 2025 |
| Therapeutics Inc Knight | 10% owner | 1,766,966 | Jul 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Geoffrey S. Dow President and CEO, Director | Jun 12, 2026 | Buy | +7,350 | $1.38 | $10.14K | 24,131 |
| Geoffrey S. Dow President and CEO, Director | Dec 15, 2025 | Buy | +9,670 | $0.80 | $7.74K | 59,618 |
| Geoffrey S. Dow President and CEO, Director | Dec 11, 2025 | Buy | +3,613 | $0.92 | $3.32K | 49,948 |
| Geoffrey S. Dow President and CEO, Director | Dec 10, 2025 | Buy | +9,350 | $0.95 | $8.88K | 46,335 |
| Geoffrey S. Dow President and CEO, Director | Sep 12, 2025 | Award | +7,201 | $1.39 | $10.01K | 33,372 |
| Geoffrey S. Dow President and CEO, Director | Jun 9, 2025 | Award | +4,376 | $2.99 | $13.08K | 26,171 |
| Cheryl Xu Director | Jun 3, 2025 | Buy | +3,000 | $2.87 | $8.61K | 13,816 |
| Cheryl Xu Director | Jun 3, 2025 | Buy | +2,000 | $2.90 | $5.80K | 15,816 |
| Kristen Landon Chief Operating Officer | Jan 17, 2025 | Award | +4,540 | – | – | 4,540 |
| Tyrone Miller CFO | Jan 17, 2025 | Award | +11,626 | – | – | 26,370 |
| Geoffrey S. Dow President and CEO, Director | Jan 17, 2025 | Award | +14,394 | – | – | 108,974 |
| Cheryl Xu Director | Dec 16, 2024 | Buy | +2,000 | $1.45 | $2.90K | 54,078 |
| Cheryl Xu Director | Dec 13, 2024 | Buy | +1,500 | $1.60 | $2.40K | 47,578 |
| Cheryl Xu Director | Dec 13, 2024 | Buy | +1,500 | $1.58 | $2.37K | 49,078 |
| Cheryl Xu Director | Dec 13, 2024 | Buy | +1,500 | $1.55 | $2.33K | 50,578 |
| Cheryl Xu Director | Dec 13, 2024 | Buy | +1,500 | $1.52 | $2.28K | 52,078 |
| Cheryl Xu Director | Dec 12, 2024 | Buy | +2,500 | $1.80 | $4.50K | 46,078 |
| Cheryl Xu Director | Dec 12, 2024 | Buy | +2,500 | $1.85 | $4.63K | 43,578 |
| Geoffrey S. Dow President and CEO, Director | Dec 9, 2024 | Buy | +35,823 | $1.27 | $45.50K | 94,580 |
| Geoffrey S. Dow President and CEO, Director | Dec 6, 2024 | Buy | +20,579 | $1.20 | $24.69K | 58,757 |
| Geoffrey S. Dow President and CEO, Director | Dec 5, 2024 | Buy | +17,549 | $1.11 | $19.48K | 38,178 |
| Geoffrey S. Dow President and CEO, Director | Nov 21, 2024 | Buy | +3,500 | $0.91 | $3.19K | 20,629 |
| Geoffrey S. Dow President and CEO, Director | Nov 20, 2024 | Buy | +1,000 | $0.92 | $920 | 17,129 |
| Geoffrey S. Dow President and CEO, Director | Nov 19, 2024 | Buy | +2,500 | $0.90 | $2.25K | 16,129 |
| Cheryl Xu Director | Aug 27, 2024 | Buy | +5,000 | $1.70 | $8.50K | 41,078 |
| Stephen Toovey Director | May 16, 2024 | Award | +4,000 | $0.22 | $880 | 14,000 |
| Geoffrey S. Dow President and CEO, Director | May 16, 2024 | Option exercise | +17,000 | $0.22 | $3.74K | 762,625 |
| Charles W. Allen Director | May 16, 2024 | Option exercise | +4,000 | $0.22 | $880 | 14,000 |
| Paul Field Director | May 16, 2024 | Option exercise | +4,000 | $0.22 | $880 | 14,000 |
| Cheryl Xu Director | May 16, 2024 | Option exercise | +2,000 | $0.22 | $440 | 228,934 |
| Tyrone Miller CFO | May 16, 2024 | Award | +15,000 | $0.22 | $3.30K | 176,928 |
| Geoffrey S. Dow President and CEO, Director | Apr 12, 2024 | Option exercise | +68,000 | $0.27 | $18.36K | 745,625 |
| Tyrone Miller CFO | Apr 12, 2024 | Award | +60,000 | $0.27 | $16.20K | 161,928 |
| Cheryl Xu Director | Feb 1, 2024 | Option exercise | +2,000 | – | – | 6,000 |
| Geoffrey S. Dow President and CEO, Director | Jan 31, 2024 | Buy | +25,974 | $0.38 | $9.87K | 703,599 |
| Cheryl Xu Director | Jan 31, 2024 | Buy | +200,000 | $0.38 | $76.00K | 424,934 |
| Therapeutics International Sa Knight – | Jul 28, 2023 | Conversion | +45,560 | $4.75 | $216.41K | 1,153,897 |
| Therapeutics International Sa Knight – | Jul 28, 2023 | Conversion | −2,162 | – | – | 78,803 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.